Current Treatment Options in Pediatrics

, Volume 4, Issue 2, pp 221–236 | Cite as

Medical Management of Vascular Anomalies

  • Reema Padia
  • Randall Bly
  • Catherine Bull
  • Amy E. Geddis
  • Jonathan Perkins
Otolaryngology (EM Arjmand and D Sidell, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Otolaryngology


Purpose of review

This chapter will summarize the most recent literature regarding the current state of medical treatment for vascular anomalies.

Recent findings

Research into the biology of these anomalies has strengthened our understanding of each anomaly and has helped to pave the way for more tailored treatment options involving molecular and/or genetic targets.


While there is still a role for surgical intervention, medical therapies that target the etiology of vascular anomalies may represent an alternative or adjunctive approach in the management of these lesions.


Infantile hemangioma Propranolol Genetics Rapamycin Lymphatic malformation Vascular anomalies 



The authors thank Eden Palmer for figure creation and preparation for publication.


Seattle Children’s Guild Association Funding Focus Award, NIH RO1 NS092772 and NIHMS 905693

Compliance with ethical standards

Conflict of Interest

Reema Padia, Catherine Bull, Randall Bly, Amy E. Geddis, and Jonathan Perkins declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and recommended reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Carrasco-Ramiro F, Peiro-Pastor R, Aguado B. Human genomics projects and precision medicine. Gene Ther. 2017;24:551–61.CrossRefPubMedGoogle Scholar
  2. 2.
    Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol. 2002;138:1567–76.CrossRefPubMedGoogle Scholar
  3. 3.
    Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope. 2010;120:676–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Fuchsmann C, Quintal MC, Giguere C, Ayari-Khalfallah S, Guibaud L, Powell J, et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg. 2011;137:471–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163:269–74.CrossRefPubMedGoogle Scholar
  6. 6.
    Dadras SS, North PE, Bertoncini J, Mihm MC, Detmar M. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol. 2004;17:1068–79.CrossRefPubMedGoogle Scholar
  7. 7.
    Costa VA, Haimowitz R, Cheng YI, Wang J, Silverman RA, Bauman NM. Social impact of facial infantile hemangiomas in preteen children. JAMA Otolaryngol Head Neck Surg. 2016;142:13–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Herlihy EP, Kelly JP, Sidbury R, Perkins JA, Weiss AH. Visual acuity and astigmatism in periocular infantile hemangiomas treated with oral beta-blocker versus intralesional corticosteroid injection. J AAPOS. 2016;20:30–3.CrossRefPubMedGoogle Scholar
  9. 9.
    Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128–40.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26:610–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Hermans DJ, van Beynum IM, Schultze Kool LJ, van de Kerkhof PC, Wijnen MH, van der Vleuten CJ. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol. 2011;64:833–8.CrossRefPubMedGoogle Scholar
  12. 12.
    North PE, Waner M, Mizeracki A, Mihm MC Jr. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31:11–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Strub GM, Kirsh AL, Whipple ME, et al. Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma. JCI Insight. 2016;1:e88856.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Michaud AP, Bauman NM, Burke DK, Manaligod JM, Smith RJ. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope. 2004;114:1231–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Elluru RG, Friess MR, Richter GT, Grimmer JF, Darrow DH, Shin JJ, et al. Multicenter evaluation of the effectiveness of systemic propranolol in the treatment of airway hemangiomas. Otolaryngol Head Neck Surg. 2015;153:452–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Hara K, Yoshida T, Kajiume T, Ohno N, Kawaguchi H, Kobayashi M. Successful treatment of Kasabach-Merritt syndrome with vincristine and diagnosis of the hemangioma using three-dimensional imaging. Pediatr Hematol Oncol. 2009;26:375–80.CrossRefPubMedGoogle Scholar
  17. 17.
    Haggstrom AN, Skillman S, Garzon MC, Drolet BA, Holland K, Matt B, et al. Clinical spectrum and risk of PHACE syndrome in cutaneous and airway hemangiomas. Arch Otolaryngol Head Neck Surg. 2011;137:680–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Enjolras O, Breviere GM, Roger G, et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr. 2004;11:99–107.CrossRefPubMedGoogle Scholar
  19. 19.
    Kothari A, Hittelman WN, Chambers TC. Cell cycle-dependent mechanisms underlie vincristine-induced death of primary acute lymphoblastic leukemia cells. Cancer Res. 2016;76:3553–61.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Cushing SL, Boucek RJ, Manning SC, Sidbury R, Perkins JA. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Otolaryngol Head Neck Surg. 2011;144:78–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Pascual-Castroviejo I. Vascular and nonvascular intracranial malformation associated with external capillary hemangiomas. Neuroradiology. 1978;16:82–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Siegel DH, Tefft KA, Kelly T, Johnson C, Metry D, Burrows P, et al. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke. 2012;43:1672–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Bingham MM, Saltzman B, Vo NJ, Perkins JA. Propranolol reduces infantile hemangioma volume and vessel density. Otolaryngol Head Neck Surg. 2012;147:338–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Zahalka AH, Arnal-Estape A, Maryanovich M, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science. 2017;358:321–6.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hayakawa Y, Wang TC. Nerves switch on angiogenic metabolism. Science. 2017;358:305–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Li D, Li P, Guo Z, Wang H, Pan W. Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway. Int J Mol Med. 2017;39:757–63.CrossRefPubMedGoogle Scholar
  28. 28.
    Wnek A, Andrzejewska E, Kobos J, Taran K, Przewratil P. Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment. Immunol Lett. 2017;185:27–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Bernabeu-Wittel J, Pereyra-Rodriguez JJ, Mantrana-Bermejo ME, Fernandez-Pineda I, de Agustin JC, Conejo-Mir J. Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients. Actas Dermosifiliogr. 2011;102:510–6.CrossRefPubMedGoogle Scholar
  30. 30.
    • Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735–46. This is a randomized, controlled trial showing the effectiveness of propranolol for infantile hemangiomas. This article follows the landmark paper in 2008 by the same author (Reference 20). CrossRefPubMedGoogle Scholar
  31. 31.
    Betlloch-Mas I, Martinez-Miravete MT, Lucas-Costa A, Martin de Lara AI, Selva-Otalaurruchi J. Outpatient treatment of infantile hemangiomas with propranolol: a prospective study. Actas Dermosifiliogr. 2012;103:806–15.CrossRefPubMedGoogle Scholar
  32. 32.
    Zaher H, Rasheed H, Hegazy RA, Hegazy RA, Abdelhalim DM, Gawdat HI. Oral propranolol: an effective, safe treatment for infantile hemangiomas. Eur J Dermatol. 2011;21:558–63.PubMedGoogle Scholar
  33. 33.
    Snir M, Reich U, Siegel R, Zvulunov A, Friling R, Goldenberg-Cohen N, et al. Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol. Eye (Lond). 2011;25:1627–34.CrossRefGoogle Scholar
  34. 34.
    Perkins JA, Chen BS, Saltzman B, Manning SC, Parikh SR. Propranolol therapy for reducing the number of nasal infantile hemangioma invasive procedures. JAMA Otolaryngol Head Neck Surg. 2014;140:220–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Boucek RJ Jr, Kirsh AL, Majesky MW, Perkins JA. Propranolol responsiveness in vascular tumors is not determined by qualitative differences in adrenergic receptors. Otolaryngol Head Neck Surg. 2013;149:772–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Song J, Ouyang TX, Huang YY, et al. Comparative study on pathology of non involuting congenital hemangioma and infantile hemangioma. Zhonghua Zheng Xing Wai Ke Za Zhi. 2011;27:178–81.PubMedGoogle Scholar
  37. 37.
    Rogers M, Lam A, Fischer G. Sonographic findings in a series of rapidly involuting congenital hemangiomas (RICH). Pediatr Dermatol. 2002;19:5–11.CrossRefPubMedGoogle Scholar
  38. 38.
    Berenguer B, Mulliken JB, Enjolras O, Boon LM, Wassef M, Josset P, et al. Rapidly involuting congenital hemangioma: clinical and histopathologic features. Pediatr Dev Pathol. 2003;6:495–510.CrossRefPubMedGoogle Scholar
  39. 39.
    Parikh SR, Darrow DH, Grimmer JF, Manning SC, Richter GT, Perkins JA. Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns. JAMA Otolaryngol Head Neck Surg. 2013;139:153–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Tang LY, Hing JW, Tang JY, et al. Predicting complications with pretreatment testing in infantile haemangioma treated with oral propranolol. Br J Ophthalmol. 2016;100:902–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg. 2011;64:292–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Salice P, Giovanni Bianchetti M, Giavarini A, Gondoni E, Cavalli R, Maria Colli A, et al. Cardiovascular profile of propranolol after multiple dosing in infantile hemangioma. Pharmacology. 2017;99:75–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Puttgen KB, Summerer B, Schneider J, Cohen BA, Boss EF, Bauman NM. Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. Ann Otol Rhinol Laryngol. 2013;122:550–4.CrossRefPubMedGoogle Scholar
  44. 44.
    Nguyen HP, Pickrell BB, Wright TS. Beta-blockers as therapy for infantile hemangiomas. Semin Plast Surg. 2014;28:87–90.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Kennedy TL, Whitaker M, Pellitteri P, Wood WE. Cystic hygroma/lymphangioma: a rational approach to management. Laryngoscope. 2001;111:1929–37.CrossRefPubMedGoogle Scholar
  46. 46.
    Churchill P, Otal D, Pemberton J, Ali A, Flageole H, Walton JM. Sclerotherapy for lymphatic malformations in children: a scoping review. J Pediatr Surg. 2011;46:912–22.CrossRefPubMedGoogle Scholar
  47. 47.
    Balakrishnan K, Menezes MD, Chen BS, Magit AE, Perkins JA. Primary surgery vs primary sclerotherapy for head and neck lymphatic malformations. JAMA Otolaryngol Head Neck Surg. 2014;140:41–5.CrossRefPubMedGoogle Scholar
  48. 48.
    Ma J, Biao R, Lou F, et al. Diagnosis and surgical treatment of cervical macrocystic lymphatic malformations in infants. Exp Ther Med. 2017;14:1293–8.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Malic CC, Guilfoyle R, Courtemanche RJM, Arneja JS, Heran MKS, Courtemanche DJ. Lymphatic malformation architecture: implications for treatment with OK-432. J Craniofac Surg. 2017;28:1721–4.CrossRefPubMedGoogle Scholar
  50. 50.
    de Serres LM, Sie KC, Richardson MA. Lymphatic malformations of the head and neck. A proposal for staging. Arch Otolaryngol Head Neck Surg. 1995;121:577–82.CrossRefPubMedGoogle Scholar
  51. 51.
    Adams MT, Saltzman B, Perkins JA. Head and neck lymphatic malformation treatment: a systematic review. Otolaryngol Head Neck Surg. 2012;147:627–39.CrossRefPubMedGoogle Scholar
  52. 52.
    Perkins JA, Maniglia C, Magit A, Sidhu M, Manning SC, Chen EY. Clinical and radiographic findings in children with spontaneous lymphatic malformation regression. Otolaryngol Head Neck Surg. 2008;138:772–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Smith MC, Zimmerman MB, Burke DK, Bauman NM, Sato Y, Smith RJH, et al. Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope. 2009;119:107–15.CrossRefPubMedGoogle Scholar
  54. 54.
    Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics. 2016;137:e20153257.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Karki R, Pandya D, Elston RC, Ferlini C. Defining "mutation" and "polymorphism" in the era of personal genomics. BMC Med Genet. 2015;8:37.Google Scholar
  56. 56.
    Glaser K, Dickie P, Neilson D, Osborn A, Dickie BH. Linkage of Metabolic Defects to Activated PIK3CA Alleles in Endothelial Cells Derived from Lymphatic Malformation. Lymphat Res Biol. 2018;16(1):43–55.CrossRefPubMedGoogle Scholar
  57. 57.
    Perez-Garijo A, Steller H. Spreading the word: non-autonomous effects of apoptosis during development, regeneration and disease. Development. 2015;142:3253–62.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    • Perkins JA. New Frontiers in our understanding of lymphatic malformations of the head and neck: natural history and basic research. Otolaryngol Clin N Am. 2018;51:147–58. This is a review of lymphatic malformations. The article highlights the clinical characteristics of lymphatic malformations and discusses the molecular contributions to the development of the disease.CrossRefGoogle Scholar
  59. 59.
    Arriola Apelo SI, Lamming DW. Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island. J Gerontol A Biol Sci Med Sci. 2016;71:841–9.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Sasongko TH, Ismail NF, Zabidi-Hussin Z. Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst Rev. 2016;7:CD011272.PubMedGoogle Scholar
  61. 61.
    Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145:101–6.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Strychowsky JE, Rahbar R, O'Hare MJ, Irace AL, Padua H, Trenor CC 3rd. Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation. Laryngoscope. 2018;128:269–76.CrossRefPubMedGoogle Scholar
  63. 63.
    Kim D, Benjamin L, Wysong A, Hovsepian D, Teng J. Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone. Dermatol Ther. 2015;28:218–21.CrossRefPubMedGoogle Scholar
  64. 64.
    Harsha WJ, Crawford JV, Sorensen DM. An unusual case of adult airway obstruction from a lymphovenous malformation. Ear Nose Throat J. 2008;87:402–4.PubMedGoogle Scholar
  65. 65.
    Wagner KM, Lokmic Z, Penington AJ. Prolonged antibiotic treatment for infected low flow vascular malformations. J Pediatr Surg. 2018;53:798–801.Google Scholar
  66. 66.
    Tempero RM, Hannibal M, Finn LS, Manning SC, Cunningham ML, Perkins JA. Lymphocytopenia in children with lymphatic malformation. Arch Otolaryngol Head Neck Surg. 2006;132:93–7.CrossRefPubMedGoogle Scholar
  67. 67.
    Balakrishnan K, Bauman N, Chun RH, Darrow DH, Grimmer JF, Perkins JA, et al. Standardized outcome and reporting measures in pediatric head and neck lymphatic malformations. Otolaryngol Head Neck Surg. 2015;152:948–53.CrossRefPubMedGoogle Scholar
  68. 68.
    Benoiton LA, Chan K, Steiner F, FitzJohn T, Tan ST. Management of Orbital and Periorbital Venous Malformation. Front Surg. 2017;4:27.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    • Seront E, Vikkula M, Boon LM. Venous malformations of the head and neck. Otolaryngol Clin N Am. 2018;51:173–84. This review provides details about venous malformations and various treatment options. CrossRefGoogle Scholar
  70. 70.
    Dasgupta R, Patel M. Venous malformations. Semin Pediatr Surg. 2014;23:198–202.CrossRefPubMedGoogle Scholar
  71. 71.
    Hung JW, Leung MW, Liu CS, et al. Venous malformation and localized intravascular coagulopathy in children. Eur J Pediatr Surg. 2017;27:181–4.PubMedGoogle Scholar
  72. 72.
    Dompmartin A, Vikkula M, Boon LM. Venous malformation: update on aetiopathogenesis, diagnosis and management. Phlebology. 2010;25:224–35.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Steiner F, FitzJohn T, Tan ST. Surgical treatment for venous malformation. J Plast Reconstr Aesthet Surg. 2013;66:1741–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Tieu DD, Ghodke BV, Vo NJ, Perkins JA. Single-stage excision of localized head and neck venous malformations using preoperative glue embolization. Otolaryngol Head Neck Surg. 2013;148:678–84.CrossRefPubMedGoogle Scholar
  75. 75.
    Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet 2007; 16 Spec No. 2:R140–149.Google Scholar
  76. 76.
    Redondo P. The hidden face of venous malformations: a multidisciplinary therapeutic approach. Arch Dermatol. 2008;144:922–6.PubMedGoogle Scholar
  77. 77.
    Soblet J, Limaye N, Uebelhoer M, Boon LM, Vikkula M. Variable somatic TIE2 mutations in half of sporadic venous malformations. Mol Syndromol. 2013;4:179–83.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet. 2009;41:118–24.CrossRefPubMedGoogle Scholar
  79. 79.
    Boscolo E, Limaye N, Huang L, Kang KT, Soblet J, Uebelhoer M, et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest. 2015;125:3491–504.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Wieck MM, Nowicki D, Schall KA, Zeinati C, Howell LK, Anselmo DM. Management of pediatric intramuscular venous malformations. J Pediatr Surg. 2017;52:598–601.CrossRefPubMedGoogle Scholar
  81. 81.
    Rivas S, Lopez-Gutierrez JC, Diaz M, Andres AM, Ros Z. Venous malformations. Diagnosis and treatment during the childhood. Cir Pediatr. 2006;19:77–80.PubMedGoogle Scholar
  82. 82.
    Rosenberg TL, Suen JY, Richter GT. Arteriovenous malformations of the head and neck. Otolaryngol Clin N Am. 2018;51:185–95.CrossRefGoogle Scholar
  83. 83.
    Han HH, Choi JS, Seo BF, et al. Successful treatment of posttraumatic arteriovenous malformation of the lower lip. J Craniofac Surg. 2015;26:e199–201.CrossRefPubMedGoogle Scholar
  84. 84.
    Liu AS, Mulliken JB, Zurakowski D, Fishman SJ, Greene AK. Extracranial arteriovenous malformations: natural progression and recurrence after treatment. Plast Reconstr Surg. 2010;125:1185–94.CrossRefPubMedGoogle Scholar
  85. 85.
    Bradley JP, Zide BM, Berenstein A, Longaker MT. Large arteriovenous malformations of the face: aesthetic results with recurrence control. Plast Reconstr Surg. 1999;103:351–61.CrossRefPubMedGoogle Scholar
  86. 86.
    Pekkola J, Lappalainen K, Vuola P, Klockars T, Salminen P, Pitkaranta A. Head and neck arteriovenous malformations: results of ethanol sclerotherapy. AJNR Am J Neuroradiol. 2013;34:198–204.CrossRefPubMedGoogle Scholar
  87. 87.
    Nikolaev SI, Vetiska S, Bonilla X, et al. Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med. 2018;378:250–61.CrossRefPubMedGoogle Scholar
  88. 88.
    Al-Olabi L, Polubothu S, Dowsett K, et al. Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Invest. 2018;128(4):1496–508.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Couto JA, Huang AY, Konczyk DJ, et al. Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation. Am J Hum Genet. 2017;100:546–54.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Reema Padia
    • 1
    • 2
  • Randall Bly
    • 1
    • 2
  • Catherine Bull
    • 1
    • 2
  • Amy E. Geddis
    • 3
  • Jonathan Perkins
    • 1
    • 2
  1. 1.Division of Pediatric Otolaryngology, Department of SurgerySeattle Children’s HospitalSeattleUSA
  2. 2.Department of Otolaryngology-Head and Neck SurgeryUniversity of Washington School of MedicineSeattleUSA
  3. 3.Cancer and Blood Disorders ClinicSeattle Children’s HospitalSeattleUSA

Personalised recommendations